What would you like to look for?
Site search
Search filters

Inositec AG acquired by Vifor Pharma

23 November 2021

Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

GlycoEra AG raises CHF 45m to Develop Novel Glycoengineering Platform

11 November 2021

GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.

MiniNaviDent AG enters into Cooperation with Straumann

5 November 2021

MiniNaviDent has received an investment by Straumann Holding AG to further develop and market its DENACAM system, a miniaturized dynamic navigation system for dental implants. Furthermore, the company has simultaneously entered...

CRK joins the MYTY Group

28 October 2021

The full-service PR and communications agency cR Kommunikation AG with offices in Bern, Basel and Zurich has joined the MYTY Group, a leading agency network in the DACH region.

Anjarium Biosciences Raises CHF 55.5m (USD 61m) Series A Financing

21 September 2021

Anjarium Biosciences AG, a biotech company in Schlieren (ZH) focused on creating and delivering a new class of non-viral gene therapies has closed a CHF55.5m Series A Financing.

EGO Movement and TVS Motor agree on a strategic partnership

21 September 2021

The fast-growing Swiss e-mobility company EGO Movement (the GO AG) has agreed on a long-term strategic partnership with the leading Indian mobility group TVS Motor.

Kuros Biosciences enters royalty purchase agreement with Xoma

20 July 2021

Kuros to receive USD 7m up front and retain the potential to receive up to USD 166.5m in future revenues under a royalty purchase agreement with XOMA Corporation

TargImmune financing round with CHF 17.7m.

16 July 2021

TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m.

Novartis acquires option to acquire Zurich-based startup Cellerys

13 July 2021

Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching an innovative therapy to combat multiple sclerosis (MS).

Swiss Nuclides raises CHF 2.6m in Series A Financing

23 June 2021

Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m.